14-Hydroxycodeinone Purification via Selective Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current processes for producing opioid compounds like oxycodone and oxymorphone result in high levels of 14-hydroxycodeinone and 8,14-dihydroxy-7,8-dihydrocodeinone impurities, which are genotoxic and require reduction to low ppm levels to ensure safety, posing challenges in achieving acceptable purity and stability during synthesis.
Innovation Solution
A process involving the oxidation of thebaine and oripavine using peroxyacids formed in situ from carboxylic acids and hydrogen peroxide, followed by recrystallization, to reduce the levels of 8,14-dihydroxy-7,8-dihydrocodeinone and 8,14-dihydroxy-7,8-dihydromorphinone impurities, resulting in higher purity and easier filtration and processing of 14-hydroxycodeinone and 14-hydroxymorphinone compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If thebaine is oxidized using peroxyacids to produce 14-hydroxycodeinone, then the production efficiency is improved, but the level of genotoxic impurities (8,14-dihydroxy-7,8-dihydrocodeinone) increases
Solution Approach 1:
The patent extracts and removes the genotoxic impurity 8,14-dihydroxy-7,8-dihydrocodeinone from the reaction mixture through selective crystallization. By controlling temperature and solvent conditions, the impurity is separated from the desired 14-hydroxycodeinone product, allowing high-yield oxidation while eliminating the harmful byproduct to meet FDA purity requirements
Solution Approach 2:
The patent applies parameter changes by optimizing reaction conditions including temperature control during oxidation, pH adjustment, and solvent selection to minimize impurity formation. The crystallization step uses controlled temperature reduction and solvent evaporation to selectively precipitate the impurity while maintaining product quality
2Productivity
If oxidation conditions are intensified to increase production rate, then productivity improves, but impurity formation increases making purification more difficult
Solution Approach 1:
The patent converts the harmful effect of impurity formation into a beneficial separation process. The genotoxic impurity 8,14-dihydroxy-7,8-dihydrocodeinone is intentionally allowed to form during oxidation, then selectively crystallized and removed in a subsequent purification step, transforming the purification challenge into a controlled separation advantage
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process effectively reduces impurity levels to below 10 ppm, enhancing the purity and processing ease of 14-hydroxycodeinone and 14-hydroxymorphinone, thereby improving the safety and quality of oxycodone and oxymorphone products by minimizing genotoxic compounds.
Implementation Method 1
oxidation of thebaine and oripavine using peroxyacids formed in situ from carboxylic acids and hydrogen peroxide
Implementation Method 2
cooling the mixture to crystallize 14-hydroxycodeinone
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Improved processes for making opioid products having low impurity levels including making 14-hydroxycodeinone and 14-hydroxymorphinone from thebaine and oripavine, respectively.